All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. Digital educational resources delivered on the Multiple Myeloma Hub are supported by an educational grant from Janssen Biotech, Inc. View funders.
IMMagine-1: Preliminary phase II results of anitocabtagene autoleucel in patients with triple-class exposed RRMM
Bookmark this article
|
IMMagine-1 (NCT05396885) is a phase II, single-arm, open-label study investigating the efficacy and safety of the BCMA-directed CAR T-cell therapy anitocabtagene autoleucel (anito-cel; formerly known as CART-ddBCMA) in patients who have received ≥3 prior lines of therapy, including a prior proteasome inhibitor, immunomodulatory agent, and CD38-targeted therapy, and are refractory to their most recent therapy.1 The primary endpoint is ORR per 2016 IMWG criteria.1 Preliminary findings from the safety evaluable (n = 98) and efficacy evaluable (n = 86) populations were presented at the 66th ASH Annual Meeting and Exposition by Freeman.1 |
| Key learnings |
| At a median follow-up of 9.5 months the ORR was 97%, with 93.1% of evaluable patients achieving MRD negativity at a minimum sensitivity of 10−5. The OS rate was 96.5% at both 6 and 12 months. |
| 83% of patients had CRS of any grade, with a median onset of 4 days and a median duration of 3 days. 86% of patients had CRS of Grade ≤1, including 17% of patients with no CRS. |
| Only 9% of patients developed ICANS, with no Grade 4 or 5 cases, and all cases resolved. The most common Grade ≥3 TEAEs were cytopenias, with Grade 3/4 neutropenia in 54% of patients, anemia in 22%, and thrombocytopenia in 20%. |
| Anito-cel demonstrated deep, durable responses in this triple-class exposed RRMM patient population with a manageable safety profile. Recruitment to the IMMagine-1 study is ongoing, with an estimated trial completion date of May 2025. |
Abbreviations: anito-cel, anitocabtagene autoleucel; ASH, American Society of Hematology; CAR, chimeric antigen receptor; CRS, cytokine release syndrome; ICANS, immune effector cell-associated neurotoxicity syndrome; IMWG, International Myeloma Working Group; ORR, overall response rate; MRD, measurable residual disease; RRMM, relapsed/refractory multiple myeloma; TREAE, treatment-emergent adverse event.
- Freeman CL, et al. Phase 2 registrational study of anitocabtagene autoleucel for the treatment of patients with relapsed and/or refractory multiple myeloma: Preliminary results from the IMMagine-1 trial. Oral abstract #3031. 66th American Society of Hematology (ASH) Annual Meeting and Exposition; Dec 10, 2024; San Deigo, US.
Your opinion matters
1 vote - 42 days left ...
Newsletter
Subscribe to get the best content related to multiple myeloma delivered to your inbox